[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632601":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":19,"responsibleParty":35,"collaborators":37,"id":40,"slug":7,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":41,"sex":46,"minAge":47,"maxAge":7,"enrollmentInfo":48,"targetDuration":51,"studyType":52,"phases":7,"briefSummary":53,"conditions":54,"keywords":7,"overallStatus":60,"whyStopped":7,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"Weill Cornell Medical College in Qatar","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"Charbel Abi Khalil","Weill Cornell Medicine-Qatar","PRINCIPAL_INVESTIGATOR",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Charbel Abi Khalil Prof","CONTACT","+ 974 4492 8484","cha2022@qatar-med.cornell.edu",[20],{"facility":21,"status":7,"city":22,"state":7,"zip":7,"country":23,"cosmosGeoPoint":24,"geoPoint":29,"contacts":30},"Hamad Medical Corporation","Doha","Qatar",{"type":25,"coordinates":26},"Point",[27,28],51.53096,25.28545,{"lat":28,"lon":27},[31],{"name":32,"role":16,"phone":33,"phoneExt":7,"email":34},"Nidal Asaad MD","+974 44390220","nasaad@hamad.qa",{"type":36,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[38],{"name":21,"class":39},"INDUSTRY","100632601",false,"NCT07515807","Qatar Cardiometabolic Retrospective Cohort-Analysis Using Artificial Intelligence","QCRC-AI","Inclusion Criteria:\n\n* Age ≥ 18\n* Qatari and Arab participants\n* Participants admitted for Acute Coronary Syndrome (ACS) or Acute Heart Failure (AHF)\n* Metabolic disease: Diabetes (HbA1C ≥ 6.5% or any HbA1C if a patient is on an antidiabetic agent) or pre-diabetes: 5.7% ≤ HbA1c ≤ 6.4%\n\nExclusion Criteria:\n\n* Non-Qatari or non-Arab participants\n* Non-diabetic: HbA1C \\\u003C 5.7%\n* This chart review involves no direct interaction with individuals. Prisoners are not a focus of this study, and incarceration status is not identifiable in the records reviewed.","ALL","18 Years",{"count":49,"type":50},10000,"ESTIMATED","2 Years","OBSERVATIONAL","Cardiovascular disease is the leading cause of death worldwide, and individuals with diabetes or other cardiometabolic conditions are at increased risk of adverse cardiovascular outcomes. Although advances in prevention and treatment have reduced cardiovascular events globally, cardiometabolic disease continues to represent a significant health burden, particularly in regions with high diabetes prevalence. In Qatar and other Gulf Cooperation Council countries, the prevalence of diabetes and obesity is increasing, contributing to a high proportion of participants presenting with acute coronary syndrome who have type 2 diabetes or prediabetes. This observational study will use electronic medical record data from patients hospitalized at the Heart Hospital with acute coronary syndrome and a concomitant diagnosis of diabetes or prediabetes. The study will assess trends in cardiovascular risk factors and cardiovascular events, including readmission and mortality. An artificial intelligence component will be used to develop and validate machine learning based risk prediction models to forecast adverse cardiovascular outcomes in participants with cardiometabolic disease. These models will integrate clinical, biochemical, imaging, and other non-invasive data routinely collected during participants care to identify predictors of cardiovascular events.",[55,56,57,58,59],"Cardio Vascular Disease","Acute Coronary Syndromes (ACS)","Type 2 Diabetes","Pre Diabetes","Artifical Intelligence","NOT_YET_RECRUITING","2026-04-15",{"date":63,"type":64},"2026-04-21","ACTUAL",{"date":66,"type":50},"2026-07-16",{"date":68,"type":50},"2030-07-16",{"name":5,"class":6},1]